Mayo Clinic's CAR-T Cell Therapy Program offers a new cancer immunotherapy that involves genetically modifying T cells to activate the immune system to recognize and destroy certain cancers. Chimeric antigen receptor (CAR)-T cell therapy, also known as CAR-T cell therapy, was approved by the Food and Drug Administration in October 2017.

CAR-T cell therapy is not the same as stem cell transplant or chemotherapy. CAR-T cell therapy may be a treatment option for:

  • Relapsed, refractory B-cell acute lymphoblastic leukemia
  • Relapsed, refractory B-cell non-Hodgkin's lymphoma
  • Relapsed, refractory mantle cell lymphoma
  • Relapsed, refractory follicular lymphoma
  • Relapsed, refractory multiple myeloma
  • Other types of cancer and medical conditions undergoing clinical studies

See full overview

CAR-T Cell Therapy Program